Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer
- Citation:
- Clin Cancer Res vol 24 (21) 5292-304
- Year:
- 2018
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Program:
- TRP
- Primary Committee:
- Sequencing
- Sec. Committees:
- Breast
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180838, U10CA180858, U10CA180867, P50-CA58223-09A1, U10CA180888, U10CA180801, U24CA196171
- Corr. Author:
- Authors:
- Maki Tanioka Cheng Fan Joel S Parker Katherine A Hoadley Zhiyuan Hu Yan Li Terry M Hyslop Brandelyn N Pitcher Matthew G Soloway Patricia A Spears Lynn N Henry Sara Tolaney Chau T Dang Ian E Krop Lyndsay N Harris Donald A Berry Elaine R Mardis Eric P Winer Clifford A Hudis Lisa A Carey Charles M Perou
- Networks:
- KAISER, LAPS-CT018, LAPS-MA036, LAPS-NC007, LAPS-NY016
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: